SAN FRANCISCO (MarketWatch) -- Taro Pharmaceutical Industries Ltd. is initiating a dose-escalation study of its proprietary T2000 compound, whose efficacy in the treatment of essential tremor is being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results